Condition: Prostate Cancer · Sponsor: Medical University of South Carolina
This study will evaluate whether simvastatin reduces intraprostatic immunosuppressive microenvironment through YAP-mediated T-reg dysfunction, and increases intraprostatic anti-tumor immune response in men recently diagnosed with localized prostate cancer electing to receive prostatectomy for their care. Half the men will be randomized to receive statins for 8 weeks prior to their surgery, while the other half will receive standard of care.
This description comes directly from the study's public registry record.
Alan Brisendine · 843-792-9007 · brisend@musc.edu
Jasmin M Brooks · 8439067139 · brooksjm@musc.edu
Always discuss trial participation with your own doctor first.
| Emory University | Atlanta, Georgia, United States | Not Yet Recruiting |
| Hollings Cancer Center at Medical University of South Carolina | Charleston, South Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05586360